Haemonetics (HAE) Shares Outstanding (Weighted Average) (2009 - 2026)

Haemonetics has reported Shares Outstanding (Weighted Average) for 18 years, with the latest figure at $47.2 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) fell 6.26% year-over-year to $47.2 million; the trailing twelve-month figure through Mar 2026 stood at $47.2 million (down 6.26% YoY), and the FY2026 full-year result was $47.2 million, down 6.26% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $47.2 million, down from $47.5 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $51.2 million in Q3 2022, with the low at $47.2 million in Q1 2026.
• Average Shares Outstanding (Weighted Average) over 5 years is $50.1 million, with a median of $50.7 million recorded in 2023.
• Year-over-year, Shares Outstanding (Weighted Average) grew 0.79% in 2024 and fell 6.5% in 2025.
• Tracing HAE's Shares Outstanding (Weighted Average) over 5 years: stood at $50.5 million in 2022, then rose by 0.34% to $50.7 million in 2023, then retreated by 0.78% to $50.3 million in 2024, then retreated by 5.55% to $47.5 million in 2025, then decreased by 0.67% to $47.2 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $47.2 million (Q1 2026), $47.5 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.

Peer Comparison